|
|
Post by mannmade on Apr 12, 2019 11:18:52 GMT -5
Yes but they did not adjust nor did they understand how to titrate.
|
|
|
|
Post by mannmade on Apr 12, 2019 11:07:39 GMT -5
I am not advocating for either the sale of Afrezza or the company. And for the record, I never thought TV ads would be the answer. They are necessary to a degree for reasons I have previously posted. And you statement is really apples to oranges when you compare the past Sanofi rights payments for a then new Afrezza to the valuation of the whole company today.
Nonetheless, in answer to your question a lot has changed since Sanofi bought and then terminated their deal with mnkd. Consider the following has happened since mnkd received back the rights to Afrezza:
1. Rev has increased over Sanofi peak many times over on less marketing spend
2. ADA/SOC has become slightly more positive towards Afrezza
3. The Stat Study proves the benefits of Afrezza
4. Tresiba was launched and when paired with Afrezza appears to give significantly better than normal results
5. CGM's have become much more main stream with much more room for growth, showing the beneifts of Afrezza in real time and for TIR
6. The Facebook page and other social media adopters are growing
7. The tritation issues and lung test issues are no longer issues
8. Vdex has emerged to support what everyone knows about Afrezza's effectiveness.
9. Peds study is well underway
10. Dr. K was hired
11. JDRF, diatribe and other major diabetes orgs have come out in support of Afrezza, no longer in doubt by them
12. One drop partnership
13. People on Afrezza have dropped the pump in favor of a cgm
As for the company:
1. Debt has been significantly reduced
2. Company now has a sales force (effectiveness is up for debate to be candid)
3. Uthr deal with first milestone validating TS and the deal itself
4. UTHR has said Trep T will replace current Tyvaso
5. RLS is progressing
6. Second Uthr moecule on the horizon
7. Hundreds of patents good into the 2030's
8. State of the art production facility
Am sure there is more but all more than enough to justify moving forward with either Afrezza and/or the company. I personally would like to wait on judgement about Afrezza until after approved and on the market for peds to see the reaction on sales 12 months out from that.
The "great" Steve Balmer (I say great with my tounge firmly planted in my cheek) once said about the iPhone upon its introduction, "No one will ever want or buy one of those." And so we go with Afrezza, early adopters continue to use it while new adopters continue to on board.... GLTAL's!!!
|
|
|
|
Post by mannmade on Apr 10, 2019 13:38:44 GMT -5
And how do you know he uses Afrezza?
|
|
|
|
Post by mannmade on Apr 10, 2019 10:43:47 GMT -5
Very cool! He even mentioned he may go with Mike to meet with some doctors in Arizona after the race to talk about this drug Afrezza he IS using.
|
|
|
|
Post by mannmade on Apr 10, 2019 10:21:41 GMT -5
Don't get me wrong on this... but I don't think too much will change in the way Dr. Kowalski speaks about Afrezza unless there is a new reason to do so.
Dr. K2 (Dr. Kendal being Dr.K1) has used Afrezza for several years while the JDRF's Chief Scientific Officer and is on record saying he likes it a lot. However, let's face it, it has not helped Afrezza too much as of today. I know the JDRF officially supports Afrezza and this may be due to Dr.K2's influence. However, there is no reason to think he will speak more about Afrezza in his new position as he still has a need (if not more so) to remain relatively agnostic to all pharmas and all meds which have a positive impact on treatng diabetes, even if as we all know Afrezza is the best!
|
|
|
|
Post by mannmade on Apr 10, 2019 9:49:05 GMT -5
I agree as well Boca, and the following items while not guaranteed to happen prior to the $1.60 warrants execution/expiration date are, imho, more likely than not:
1. Second UTHR milestone
2. Second UTHR molecule
3. Brazil approval
4. Canada and Mexico filings
5. Sustained Afrezza revenue trend of $1.5m plus weekly gross revenue which equals $750K weekly net or $39m net on an annualized basis which is about 35% to break even.
6. One* or more of the above will sustain price to trigger warrants in my opinion and give mnkd an extended runway into mid 2020.
*Canada and Mexico filings by themself may not be sufficient.
|
|
|
|
Post by mannmade on Apr 5, 2019 16:04:09 GMT -5
Lord Vader...  |
|
|
|
Post by mannmade on Apr 4, 2019 13:40:50 GMT -5
If you do a bit of your own research you will find the details in press anoouncements about the partnership and also some articles on the settlement. Should not be too hard to find.
|
|
|
|
Post by mannmade on Apr 4, 2019 12:18:12 GMT -5
I don’t see a thing wrong with Mike keeping up with the Afrezza Facebook page, reaching out to help a patient or two..those people are thrilled and just work that much harder to get on Afrezza, not to mention he’s doing it at 3 or 3:30 in the morning, his workday hasn’t even started yet and it only takes a second for a kind reply. He reached out to a friend of mine whose son is on Afrezza, not my client, in a similar situation ..told him to use a little less basal, it worked out perfectly. Sam and Eric can’t do everything. It has to be someone people know, can’t be some anonymous person from Mannkind. They can call Mannkind cares for many of their issues. When people get one on one care they don’t give up like they do when they’re left alone after only seeing their Endo for 10 minutes every two months. They should hire a Doctor or NP to become the face of Afrezza much like Flo the spokesperson for Progressive Insurance. Promote her/him in media as an expert on Afrezza and let that person reach out one on one. If they were also a T1, even better. Have a FB page where she/he can answer questions directly as well when people have issues with dosing, insurance etc... |
|
|
|
Post by mannmade on Apr 3, 2019 15:03:43 GMT -5
Or, Mannkind and MC want the 2.38 warrants to expire because there is bigger news pending that will move the stock up substantially and they can do an offering at the substantially higher price. Just a thought. Fingers crossed and what about the $1.6 warrants at end of the year? |
|
|
|
Post by mannmade on Apr 3, 2019 13:45:26 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" If that's a true assessment, then those shares will stay in MNKD's pocket for awhile. The next question is...where does our next shot of cash come from??? Take your pick: 1. 2nd UTHR milestone: $12.5 2. 2nd UTHR molecule: $30m 3. RLS: Milestone: $? 4. Another outside molecule partner: $? 5. Increasing Afrezza revenue 6. $1.60 warrants: $40m 7. Uthr buyin or other partnership: $? 8. Dilution Am not speculating on any of the above here. Just trying to answer your question as best I can w options I know of. |
|
|
|
Post by mannmade on Apr 3, 2019 11:37:49 GMT -5
Yes per day thank you.
|
|
|
|
Post by mannmade on Apr 3, 2019 11:03:26 GMT -5
Maybe this is why mnkd extended their offer of $5 per month to end of year?
|
|
|
|
Post by mannmade on Apr 2, 2019 9:49:12 GMT -5
Couple of questions come to mind...
1. As many have asked, has the original offer to 1,000 been reached? Would be nice to announce it has and that was so successful mnkd wants to extend fr rest of year.
2. How many are signing up and at what rate?
3. Given current rate of retention of refills, the real question is what can mnkd expect for retention? Are they dong anything differently to ensure greater retention?
4. Is this program effecting weekly symphony scripts/cannabalizing retail?
|
|
|
|
Post by mannmade on Apr 1, 2019 13:30:49 GMT -5
Am not sure we need more sales reps per se. what we need is. “Swat” team to strategically target opportunities all over the country such as major clinics or medical centers and focus on getting them on board. Kaiser was a great start although appears will need a lot of on going support and attention to grow scripts there. But at least mnkd is on the beach there...
|
|
